MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

From Medicineworld.org: Pretreating Rogue Cancer Cells With Aspirin

Cancer main Cancer news Breast cancer  


Do You Read All Of Our Cancer Blogs?

Do You Read All Of Blogs?
Do you read all of the blogs published by medicineworld.org? Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.

Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.

Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.

Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.

Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.

Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.

Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.

Janet      

Pretreating Rogue Cancer Cells With Aspirin


Pretreating Rogue Cancer Cells With Aspirin
For years, we have heard about the health benefits of taking low doses of aspirin - preventing everything from Alzheimer's disease to heart attacks and stroke. The news about aspirin just keeps getting better. As per a research findings published in the Dec. 9 issue of the Journal of Biological Chemistry, University of Pittsburgh scientists report that aspirin, combined with a promising new cancer treatment known as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), can induce cancer cells previously resistant to TRAIL treatment to self-destruct. The investigators say that if these findings hold up in larger studies, aspirin could become a routine treatment for helping to prevent the recurrence of a number of aggressive cancers, such as prostate and colon cancers.

"When cancers recur after initial treatment, they tend to be extremely aggressive and patient prognosis is poor," said Yong J. Lee, Ph.D., professor in the departments of surgery and pharmacology, University of Pittsburgh School of Medicine, and lead author of the study. "If we could find ways to prevent these secondary cancers from occurring, we could save a number of lives. Aspirin is a low-cost medicine that, in our studies, appears to have great potential for helping to prevent such cancer recurrences".

TRAIL is a protein that is expressed by cells of the immune system. Numerous studies have shown that TRAIL induces programmed cell death, or apoptosis, in cancer cells while having little or no effect in normal healthy cells. Apoptosis is one of several mechanisms by which damaged cells self-destruct and is the body's way of ensuring that only healthy cells reproduce. Most often, apoptosis eliminates rogue cells with damaged DNA or cells growing too quickly, but it also eliminates normal cells that have simply become obsolete as an organism grows and develops. Because cancer cells have lost their ability to undergo apoptosis, they continue to reproduce and spread their damaged progeny throughout the body.

In recent years, researchers have gained an increasingly sophisticated understanding of the mechanisms of apoptosis, which has led to the development of many therapies targeted to repairing or bypassing damaged apoptotic processes in cancer cells. TRAIL is one of the more promising of these agents, and a synthesized form of TRAIL has been shown in cell cultures and animal models to induce apoptosis alone and in combination with other drugs.

Unfortunately, studies have found that not all cancers are sensitive to TRAIL. In fact, a number of tumor cells are completely resistant to TRAIL's effects, creating an intensive search for compounds that can overcome this resistance. Based on other studies showing that aspirin can prevent the formation of tumors caused by ultraviolet radiation and carcinogens, Dr. Lee and his colleagues decided to test the ability of this compound to increase the sensitivity of TRAIL-resistant cancer cells to apoptosis. To do this, they treated human prostate cancer cells with aspirin and then treated the cells with a combination of TRAIL and/or aspirin. Cancer cells treated with either aspirin or TRAIL alone showed little or no cell death. However, pretreatment of the TRAIL-resistant cancer cells with aspirin promoted cell death when TRAIL was added.

To determine whether TRAIL was indeed inducing apoptosis in the aspirin-sensitized cells or killing the cells through some other mechanism, Dr. Lee and his colleagues looked for molecular signs of apoptosis. In the cancer cells pretreated with aspirin followed by TRAIL, there was significant cleavage, or cutting up, of a compound known as poly (ADP-ribose) polymerase, or PARP. PARP cleavage, a hallmark feature of apoptosis, did not occur in normal cells nor in cancer cells treated with aspirin alone.

Interestingly, the investigators discovered that, for PARP cleavage to occur, it was necessary to pretreat cancer cells with aspirin at least 12 hours before the administration of TRAIL. Dr. Lee and colleagues also found that aspirin therapy causes cancer cells to decrease their production of a cellular protein known as Bcl-2, which has been shown in numerous studies to protect healthy cells from premature apoptosis. Decreased Bcl-2 production was the result of suppression of the Bcl-2 gene. Furthermore, when the investigators induced prostate and colon cancer cells to produce excess amounts of the Bcl-2 protein in the cells, the cells were still resistant to TRAIL-induced apoptosis even when they were pretreated with aspirin. According to Dr. Lee, this suggests that TRAIL induces apoptosis via cellular mitochondria.

"Bcl-2 inhibits the release of a compound known as cytochrome c from mitochondria, an organelle in the cell that regulates energy production as well as cell death. Therefore, we suspected that TRAIL might be inducing cell death through mitochondria-mediated apoptosis. In this study we demonstrated that aspirin can down-regulate Bcl-2 gene expression and consequently change the electrical potential of the mitochondrial membrane in cancer cells, thereby releasing cytochrome c and other apoptotic proteins".

Dr. Lee and colleagues believe these findings could soon be applied in the clinical setting and result in the increased effectiveness of TRAIL for treating many aggressive cancers, especially those that overexpress the human epidermal growth factor receptor 2 (HER-2/neu) gene. This gene is amplified up to 30 percent in some human cancers, which leads to an increase in the expression of the HER-2/neu protein on the cell surface. Numerous studies suggest that a high concentration of the HER-2/neu protein on the surface of cancer cells makes them more aggressive and difficult to treat. In this study, Dr. Lee and coworkers demonstrated that the combination of aspirin and TRAIL undercuts the effects of HER-2/neu overexpression.

"HER-2/neu overexpression in cancer cells, such as prostate and colon, is associated with a higher cell proliferation rate, faster metastases and greater tumor burden," explained Dr. Lee. "It is our hope that aspirin and other agents we are currently testing can negate this effect and dramatically improve the prognosis of patients with these types of cancer".

In addition to Dr. Lee, other contributors to this study include Kim M. Kim, Ph.D., and Jae J. Song, Ph.D., department of surgery, University of Pittsburgh School of Medicine, and Jee Young An, Ph.D., and Yong Tae Kwon, Ph.D., Center for Pharmacogenetics, department of pharmaceutical sciences, University of Pittsburgh School of Pharmacy.

This study was supported by grants from the National Cancer Institute, National Institutes of Health, the Elsa U. Pardee Foundation, The Pittsburgh Foundation, the Department of Defense Prostate Program Fund and Department of Defense Prostate Traineeship.


Source: University of Pittsburgh Medical Center


Did you know?
For years, we have heard about the health benefits of taking low doses of aspirin - preventing everything from Alzheimer's disease to heart attacks and stroke. The news about aspirin just keeps getting better. As per a research findings published in the Dec. 9 issue of the Journal of Biological Chemistry, University of Pittsburgh scientists report that aspirin, combined with a promising new cancer treatment known as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), can induce cancer cells previously resistant to TRAIL treatment to self-destruct. The investigators say that if these findings hold up in larger studies, aspirin could become a routine treatment for helping to prevent the recurrence of a number of aggressive cancers, such as prostate and colon cancers.

Medicineworld.org: Pretreating Rogue Cancer Cells With Aspirin

Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main| Updates in oncology| Acute myeloid leukemia|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.